Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early breast cancer
- Cuzick, Jack, Dowsett, Mitch, Howell, Anthony, Buzdar, Aman U., Forbes, John F., Pineda, Silvia, Wale, Christopher, Salter, Janine, Quinn, Emma, Zabaglo, Lila, Mallon, Elizabeth, Green, Andrew R., Ellis, Ian O.
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
- Dowsett, Mitch, Allred, Craig, Bishop, Hugh, Ellis, Ian, Larsimont, Danis, Sasano, Hironobu, Carder, Pauline, Cussac, Antonio L., Knox, Fiona, Speirs, Valerie, Forbes, John, Buzdar, Aman, Knox, Jill, Quinn, Emma, Salter, Janine, Wale, Chris, Cuzick, Jack, Houghton, Joan, Williams, Norman, Mallon, Elizabeth
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC Study
- Dowsett, Mitch, Cuzick, Jack, Howell, Anthony, Bugarini, Roberto, Baehner, Frederick L., Shak, Steven, Wale, Christopher, Forbes, John, Mallon, Elizabeth A., Salter, Janine, Quinn, Emma, Dunbier, Anita, Baum, Michael, Buzdar, Aman
Are you sure you would like to clear your session, including search history and login status?